Tenpoint Therapeutics

Tenpoint Therapeutics is a private, clinical-stage biotech developing novel treatments for age-related vision decline, with a lead program in presbyopia. The company's strategy centers on addressing key unmet needs in functional near vision, duration of effect, and tolerability for daily use. With its lead asset, BRIMOCHOL™ PF, having achieved an FDA New Drug Application (NDA) acceptance, Tenpoint is positioned for a potential near-term commercial launch in a large, underserved market. The company represents a specialized player in the ophthalmology space, aiming to set a new standard in presbyopia care.

Focused therapeutic approach for ocular rejuvenation, likely involving pharmacological, cell, or gene-based strategies to restore function in the aging lens and retina. Emphasis on formulation science for duration of effect and tolerability.

In presbyopia, Tenpoint competes directly with AbbVie's approved Vuity and other clinical-stage agents. The cataract space is currently devoid of pharmacological therapies, making it a high-risk, high-reward opportunity. In geographic atrophy, it would face competition from recently approved complement inhibitors and a pipeline of next-generation therapies from larger biopharma companies.